Biotechnology
Cancer Prevention
Health

Clovis Oncology

$16.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.16 (0.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CLVS and other stocks, options, ETFs, and crypto commission-free!

About

Clovis Oncology, Inc. Common Stock, also called Clovis Oncology, is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Read More Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Employees
468
Headquarters
Boulder, Colorado
Founded
2009
Market Cap
887.12M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.83M
High Today
$17.02
Low Today
$16.61
Open Price
$16.75
Volume
1.15M
52 Week High
$50.00
52 Week Low
$11.50

Collections

Biotechnology
Cancer Prevention
Health
Technology

News

NasdaqMay 8

Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong

Clovis Oncology, Inc. CLVS incurred adjusted loss of $1.63 per share in the first quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of $1.80. However, it was wider than the year-ago loss of $1.38 per share. Net revenues, entirely from Clovis' only marketed drug, Rubraca, were approximately $33.1 million in the quarter, up 8.9% sequentially. The top line also beat the Zacks Consensus Estimate of $31.68 million. The company had recorded total revenues of $18.5 million, entirely from Rubra...

149
Yahoo FinanceMay 7

Clovis Oncology Announces First Quarter 2019 Operating Results

BOULDER, Colo.--(BUSINESS WIRE)-- $33.1M in Rubraca ® (rucaparib) global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib with rucaparib and Bristol-Myers Squibb’s Opdivo expected to begin in mid...

43
Seeking AlphaMay 6

Clovis Oncology, Inc. Q1 2019 Earnings Preview

Clovis Oncology, Inc. (NASDAQ:CLVS) is scheduled to announce Q1 earnings results on Tuesday, May 7th, before market open. The consensus EPS Estimate is -$1.73 (-12.3% Y/Y) and the consensus Revenue Estimate is $32.1M (+73.3% Y/Y). Over the last 2 years, clvs has beaten EPS estimates 38% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 3 upward revisions and 0 downward....

94

Earnings

-$1.88
-$1.66
-$1.43
-$1.21
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.